story of the week
Outcomes of Using Subcutaneous Infliximab Biosimilar CT-P13 as Maintenance Therapy in Patients With IBD
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Gastroenterology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY)
Gastroenterology 2024 Oct 01;167(5)919-933, SB Hanauer, BE Sands, S Schreiber, S Danese, M Kłopocka, J Kierkuś, R Kulynych, M Gonciarz, A Sołtysiak, P Smoliński, S Srećković, E Valuyskikh, A Lahat, M Horyński, A Gasbarrini, M Osipenko, V Borzan, M Kowalski, D Saenko, R Sardinov, SJ Lee, S Kim, Y Bae, S Lee, S Lee, JH Lee, S Yang, J Lee, J Lee, JM Kim, G Park, WJ Sandborn, JF ColombelFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.